검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lymphodepletion |
Overview Company | Medigene AG |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | Biomarker Testing with Engineered Immune Effector Cells |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Toxicology CRS | Reported |
Clinical Primary efficacy | 0% |
Clinical ORR | 0% |
Clinical PFS | 0.99 |
Clinical OS | 4.50 |
Clinical Result source | ClinicalTrials.gov NCT05714345 |
Clinical Data Tier / Score | A · 22 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lymphodepletion |
Overview Company | Medigene AG |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | Biomarker Testing with Engineered Immune Effector Cells |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Toxicology CRS | Reported |
Clinical Primary efficacy | 0% |
Clinical ORR | 0% |
Clinical PFS | 0.99 |
Clinical OS | 4.50 |
Clinical Result source | ClinicalTrials.gov NCT05714345 |
Clinical Data Tier / Score | A · 22 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교